Treatment of vascular occlusions using ultrasonic energy and microbubbles

1. A method of treating a vascular occlusion located at a treatment site within a patient's vasculature, the method comprising:

positioning an ultrasound assembly at the treatment site;

delivering a diluted microbubble-therapeutic compound from the ultrasound assembly to the vascular occlusion, wherein the diluted microbubble-therapeutic compound has:

(1) an initial microbubble concentration of between 500,000-1,000,000 microbubble/mL; or

(2) an effective microbubble concentration of between 5,000-10,000 microbubble/mL; and

delivering ultrasonic energy from the ultrasound assembly to the vascular occlusion concurrently.

2. The method of claim 1 , wherein the dilute microbubble-therapeutic compound comprises biological or synthetic-shelled microbubbles.

3. The method of claim 2 , wherein the biological or synthetic-shelled microbubbles are less than or equal to approximately 10 micrometers in diameter.

4. The method of claim 1 , wherein the diluted microbubble-therapeutic compound and/or ultrasonic energy are delivered concurrently and continuously.

5. The method of claim 1 , wherein the ultrasonic energy has a peak rarefaction acoustic pressure less or equal to approximately 5.0 MPa.

6. A method of treating a vascular occlusion located at a treatment site within a patient's vasculature, the method comprising:

passing an ultrasound assembly through the patient's vasculature to the treatment site, wherein the ultrasound assembly comprises at least one distal fluid delivery port and at least one ultrasound radiating member;

delivering a microbubble-therapeutic compound having an initial microbubble concentration to the proximal end of the at least one distal fluid delivery port to the vascular occlusion, wherein the initial microbubble concentration is diluted to between 500,000-1,000,000 microbubble/mL, and the microbubble-therapeutic compound has a final concentration at the point of delivery to the vascular occlusion that is further reduced to 0.01% of the initial microbubble concentration; and

delivering ultrasonic energy from the ultrasound assembly to the vascular occlusion concurrent to delivering the microbubble-therapeutic compound.

7. The method of claim 6 , wherein the microbubble-therapeutic compound comprises biological or synthetic-shelled microbubbles.

8. The method of claim 7 , wherein the biological or synthetic-shelled microbubbles are less than or equal to approximately 10 micrometers in diameter.

9. The method of claim 6 , wherein the microbubble-therapeutic compound and/or ultrasonic energy are delivered continuously and concurrently.

10. The method of claim 6 , wherein the ultrasonic energy has a peak rarefaction acoustic pressure less or equal to approximately 5.0 MPa.